open access

Vol 8, No 2 (2017)
Case report
Published online: 2017-09-06
Get Citation

Successful induction and consolidation chemotherapy in 20-years-old woman with acute promyelocytic leukemia who refused to accept blood transfusion because of religious beliefs

Ilona Szypuła-Perkosz, Ewa Bodzenta, Agnieszka Barchnicka, Elżbieta Chachaj, Janusz Limon, Bożena Jaźwiec, Sebastian Grosicki
DOI: 10.5603/Hem.2017.0018
·
Hematologia 2017;8(2):152-158.

open access

Vol 8, No 2 (2017)
CASE REPORTS
Published online: 2017-09-06

Abstract

This paper describes a case of 20 years old woman with acute promyelocytic leukemia who refused to accept blood transfusion because of religious beliefs. Individualized induction chemotherapy with daunorubicin, cladribine, cytarabine and all-trans retinoic acid was administered and complete remission was achieved. Grade 4 leukopenia, anemia and thrombocytopenia was observed during induction chemotherapy. Then three consecutive consolidation cycles were given without important complications. In control molecular analysis after induction-consolidation therapy there was no PML-RARA fusion gene detected.

Abstract

This paper describes a case of 20 years old woman with acute promyelocytic leukemia who refused to accept blood transfusion because of religious beliefs. Individualized induction chemotherapy with daunorubicin, cladribine, cytarabine and all-trans retinoic acid was administered and complete remission was achieved. Grade 4 leukopenia, anemia and thrombocytopenia was observed during induction chemotherapy. Then three consecutive consolidation cycles were given without important complications. In control molecular analysis after induction-consolidation therapy there was no PML-RARA fusion gene detected.

Get Citation

Keywords

acute promyelocytic leukemia, chemotherapy, Jehovah’s Witness, blood transfusions

About this article
Title

Successful induction and consolidation chemotherapy in 20-years-old woman with acute promyelocytic leukemia who refused to accept blood transfusion because of religious beliefs

Journal

Hematology in Clinical Practice

Issue

Vol 8, No 2 (2017)

Article type

Case report

Pages

152-158

Published online

2017-09-06

DOI

10.5603/Hem.2017.0018

Bibliographic record

Hematologia 2017;8(2):152-158.

Keywords

acute promyelocytic leukemia
chemotherapy
Jehovah’s Witness
blood transfusions

Authors

Ilona Szypuła-Perkosz
Ewa Bodzenta
Agnieszka Barchnicka
Elżbieta Chachaj
Janusz Limon
Bożena Jaźwiec
Sebastian Grosicki

References (14)
  1. Sanz MA, Montesinos P, Kim HT, et al. IC-APL and PETHEMA and HOVON Groups. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol. 2015; 94(8): 1347–1356.
  2. Sanz MA, Martín G, González M, et al. Programa de Estudio y Traitmiento de las Hemopatías Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004; 103(4): 1237–1243.
  3. Sanz MA, Montesinos P, Vellenga E. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008; 112(8): 3130–3134.
  4. Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002; 99(3): 759–767.
  5. Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017; 35(6): 605–612.
  6. Burnett AK, Russell NH, Hills RK, et al. UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(13): 1295–1305.
  7. Chojnowski K, Janus A, Bliźniewska K, et al. Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah's Witness patient. Transfusion. 2016; 56(10): 2438–2442.
  8. Laszlo D, Agazzi A, Goldhirsch A, et al. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004; 72(4): 264–267.
  9. Brown NM, Keck G, Ford PA. Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma. 2008; 49(4): 817–820.
  10. Cullis JO, Duncombe AS, Dudley JM, et al. Acute leukaemia in Jehovah's Witnesses. Br J Haematol. 1998; 100(4): 664–668.
  11. Mazza P, Palazzo G, Amurri B, et al. Acute leukemia in Jehovah's Witnesses: a challenge for hematologists. Haematologica. 2000; 85(11): 1221–1222.
  12. Keane C, Mollee P, Marlton P, et al. Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Ann Hematol. 2011; 90(3): 359–360.
  13. Lin CP, Huang MJ, Liu HJ, et al. Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. Am J Hematol. 1996; 51(3): 251–252.
  14. Wandt H, Schaefer-Eckart K, Wilhelm M. Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica. 2005; 90(9): 1292–1294.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.